Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Narrative (Details)

v3.20.2
Revenue Recognition - Narrative (Details) - USD ($)
3 Months Ended 9 Months Ended 36 Months Ended 69 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2020
Dec. 31, 2019
Disaggregation of Revenue [Line Items]              
Prior period performance obligation revenue recognized     $ 1,600,000 $ 25,800,000      
Overpayment reimbursement liability $ 21,400,000   21,400,000   $ 21,400,000 $ 21,400,000 $ 27,300,000
Revenue recognized     18,376,000   $ 0    
Total revenues 428,064,000 $ 228,772,000 940,739,000 677,592,000      
Rayaldee              
Disaggregation of Revenue [Line Items]              
Revenue recognized 8,100,000 7,400,000 26,700,000 18,800,000      
Total revenues 22,010,000   67,569,000        
Transfer of intellectual property and other              
Disaggregation of Revenue [Line Items]              
Total revenues 16,864,000 21,472,000 47,297,000 58,961,000      
Pfizer | Products              
Disaggregation of Revenue [Line Items]              
Revenue recognized           $ 0  
Pfizer | Products | Transfer of intellectual property and other              
Disaggregation of Revenue [Line Items]              
Total revenues 3,100,000 $ 19,500,000 25,800,000 $ 55,100,000      
BioReference | Products | Transfer of intellectual property and other              
Disaggregation of Revenue [Line Items]              
Total revenues $ 10,000,000.0   $ 16,200,000